Quoin Pharmaceuticals (QNRX) AI Stock Analysis

• Market Cap: $4.33M
• Dividend Yield: N/A
• Average Volume (3M): 629.04K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.08
• Revenue Growth: N/A
• EPS Growth: -228.89%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.71
• Shares Outstanding: 838,977
• 10 Day Avg. Volume: 1,633,105
• 30 Day Avg. Volume: 629,040
• PEG Ratio: <0.01
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.39
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.20
• 1Y Price Target: $70.00
• Price Target Upside: 497.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $7.00 ▼(-40.27% Downside)

The score is held down primarily by weak financials (no revenue, sizable losses, and significant cash burn with negative equity), reinforced by bearish technical signals (below key moving averages with negative MACD). Positive corporate catalysts (orphan designation and breakthrough application) provide some offset, but do not outweigh the current funding and execution risks.

Positive Factors

Awareness Campaign Success

The success of the NETHERTON NOW campaign enhances Quoin's visibility and credibility in addressing rare diseases, potentially aiding future product acceptance and partnerships.

Leadership Strength

The appointment of an experienced CFO strengthens Quoin's financial leadership, which is crucial for navigating commercialization and financial challenges.

Product Pipeline Progress

Progress in clinical studies for QRX003 indicates potential for future revenue generation and market entry, critical for long-term growth.

Negative Factors

Financial Instability

The lack of revenue and reliance on external financing highlight financial instability, posing risks to operational sustainability and growth.

Negative Cash Flow

Persistent negative cash flow and dependence on external funding raise concerns about Quoin's ability to sustain operations without new revenue streams.

Lack of Profitability

The absence of revenue and profitability underscores significant challenges in achieving financial stability, impacting long-term viability.

Quoin Pharmaceuticals Business Overview & Revenue Model

Company Description

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

How the Company Makes Money

Quoin Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products. The company's revenue model primarily involves the sale of its approved drugs and potential licensing agreements with other pharmaceutical firms. As Quoin continues to advance its product candidates through clinical trials, successful approvals and subsequent market launches are anticipated to be key revenue drivers. Additionally, the company may enter into strategic partnerships or collaborations that could provide milestone payments and royalties, further contributing to its earnings. Significant factors influencing its revenue include the successful development of its pipeline products, obtaining regulatory approvals, and the establishment of distribution networks for commercializing its therapies globally.

Quoin Pharmaceuticals Financial Statement Overview

Summary

Pre-commercial with no revenue and persistent losses (TTM net loss ~-$13.8M) alongside heavy cash burn (TTM operating/free cash flow ~-$10.7M). While debt is $0, equity has turned negative (TTM ~-$1.2M) and total assets fell sharply, increasing financing and dilution risk.

Income Statement

Across annual periods and TTM (Trailing-Twelve-Months), the company reports no revenue, indicating it remains pre-commercial. Losses are persistent and sizable, with TTM net loss of about $13.8M and operating loss of about $14.2M, worsening versus FY2024. With no revenue base, profitability and margin trends are structurally weak, and the key near-term dependency is continued external funding rather than operating leverage.

Balance Sheet

Total debt is reported at $0 in the most recent periods, which reduces financial leverage risk. However, the balance sheet has weakened materially: stockholders’ equity turned negative in TTM (Trailing-Twelve-Months) (about -$1.2M) versus positive equity in FY2024 (about $9.2M), signaling accumulated losses and/or dilution effects. Total assets declined meaningfully from FY2024 (~$15.7M) to TTM (~$6.4M), reducing financial flexibility despite the absence of debt.

Cash Flow

Cash burn remains heavy and rising: TTM (Trailing-Twelve-Months) operating and free cash flow are both about -$10.7M versus about -$7.9M in FY2024. Free cash flow has improved versus the prior TTM period (positive growth noted), but absolute cash consumption is still substantial. Cash generation does not cover losses (operating cash flow is negative), meaning the company likely relies on capital raises to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-14.00M	-9.43M	-9.27M	-8.56M	-20.27M	-1.57M
Net Income	-13.77M	-8.96M	-8.69M	-9.38M	-21.46M	-2.10M
Balance Sheet
Total Assets	6.42M	15.71M	12.17M	14.46M	9.36M	1.38M
Cash, Cash Equivalents and Short-Term Investments	5.41M	14.06M	10.69M	12.85M	7.48M	323.83K
Total Debt	0.00	0.00	0.00	0.00	0.00	1.21M
Total Liabilities	7.64M	6.50M	6.51M	7.05M	8.70M	7.99M
Stockholders Equity	-1.21M	9.20M	5.66M	7.41M	657.03K	-6.61M
Cash Flow
Free Cash Flow	-10.74M	-7.86M	-7.86M	-8.73M	-6.35M	-1.46M
Operating Cash Flow	-10.74M	-7.86M	-7.86M	-8.48M	-5.72M	-1.34M
Investing Cash Flow	3.81M	-1.89M	2.19M	-10.15M	-625.00K	-125.00K
Financing Cash Flow	5.64M	10.97M	5.22M	14.01M	13.50M	1.79M

Quoin Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Negative. The current price of 11.72 is above the 20-day moving average (MA) of 9.71, below the 50-day MA of 12.90, and above the 200-day MA of 10.00, indicating a bearish trend. The MACD of -1.47 indicates Positive momentum. The RSI at 33.36 is Neutral, neither overbought nor oversold. The STOCH value of 17.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNRX.

Quoin Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JAGX	45 Neutral	$2.17M	-0.02	-370.95%	―	12.45%	-544.23%
CLDI	45 Neutral	$6.84M	-0.10	―	―	―	87.42%
QNRX	44 Neutral	$4.33M	-0.02	-655.85%	―	―	-228.89%
GLMD	44 Neutral	$3.48M	-0.17	-46.34%	―	―	70.71%
ADIL	41 Neutral	$4.36M	-0.15	-155.01%	―	―	78.52%

Quoin Pharmaceuticals Corporate Events

Quoin seeks Saudi breakthrough status for Netherton therapy

On January 20, 2026, Quoin Pharmaceuticals announced that it had filed an application with the Saudi Food and Drug Authority for Breakthrough Medicine Designation for QRX003, its lead late-stage topical candidate for Netherton Syndrome, a rare and life-threatening skin disorder. The company believes QRX003 satisfies the SFDA’s criteria for therapies addressing serious conditions with high unmet medical need, and is running two late-stage pivotal whole-body clinical trials in Netherton patients, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half of 2026. If the designation is granted, QRX003 would benefit from an accelerated review process in Saudi Arabia, potentially supporting earlier patient access and positioning the drug to become the first approved treatment for Netherton Syndrome globally, while also underpinning Quoin’s broader regulatory plans for New Drug Application filings in the United States and other territories. As of January 20, 2026, the company reported 1,616,179 American Depositary Shares outstanding, underscoring the relatively small equity base backing its rare-disease development strategy.

The most recent analyst rating on (QNRX) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Quoin Pharmaceuticals Approves New Stock Option Agreements

On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreements for stock options under the company’s 2025 Equity Incentive Plan. These agreements outline the terms for granting equity awards to directors and executive officers, including various payment methods for exercising options and conditions for awards upon termination of employment. This move aims to enhance the company’s ability to attract and retain top talent, potentially impacting its competitive position in the pharmaceutical industry.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery

On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of target loading concentrations for its two topical rapamycin delivery technologies. A 4% concentration was achieved in their topical formulation and a 5% concentration in a dermal patch system. The company plans to manufacture clinical trial batches this quarter and begin clinical testing in the first half of 2026, targeting conditions like Microcystic Lymphatic Malformations and Venous Malformations, for which there are currently no FDA-approved treatments.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.